Our lead product for severe pneumonia, plasma gelsolin, has application for COVID19.

VP, Corporate Development and Communications, Steven Cordovano

Steven Cordovano brings to BioAegis a sophisticated market perspective and broad investor network gained through years of investment experience as a highly successful fund manager.

He has worked in finance and portfolio management for 25 years. Prior to BioAegis, Mr. Cordovano was a Partner with Trivalent Partners, where he assisted emerging growth companies in developing financing and communication strategies. Steve has been an advisor to several large institutional funds. From 2005 until 2009, Mr. Cordovano was the General Partner of HealthCare 250, L.P., a fund that invested solely in small to mid-cap health care companies.

From 1994 to 2005, he was a general partner in Gulfstream Partners, L.P., a long/short hedge fund that invested in multiple-sectors of the U.S. equity markets for individuals and pension funds. The fund was ranked by Financial World Magazine as the #1 performing hedge fund over three years, from 1994 to 1996. Through 15 years of management, Mr. Cordovano achieved overall average annual returns of 15%, exceeding the market throughout that same period. Mr. Cordovano began his financial services career in the Capital Markets division of Shearson Lehman Brothers in 1984.

Mr. Cordovano attended the business school of Villanova University and received his B.A. from Manhattanville College.